JP2021520406A - Braf変異を有するがんのための組合せ治療 - Google Patents

Braf変異を有するがんのための組合せ治療 Download PDF

Info

Publication number
JP2021520406A
JP2021520406A JP2021503193A JP2021503193A JP2021520406A JP 2021520406 A JP2021520406 A JP 2021520406A JP 2021503193 A JP2021503193 A JP 2021503193A JP 2021503193 A JP2021503193 A JP 2021503193A JP 2021520406 A JP2021520406 A JP 2021520406A
Authority
JP
Japan
Prior art keywords
salt
palbociclib
cobimetinib
osimertinib
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021503193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520406A5 (cg-RX-API-DMAC7.html
Inventor
イヨウ チェン,
イヨウ チェン,
チュン ジアン,
チュン ジアン,
Original Assignee
コセラ バイオサイエンス, インコーポレイテッド
コセラ バイオサイエンス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コセラ バイオサイエンス, インコーポレイテッド, コセラ バイオサイエンス, インコーポレイテッド filed Critical コセラ バイオサイエンス, インコーポレイテッド
Publication of JP2021520406A publication Critical patent/JP2021520406A/ja
Publication of JP2021520406A5 publication Critical patent/JP2021520406A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021503193A 2018-04-08 2019-04-08 Braf変異を有するがんのための組合せ治療 Pending JP2021520406A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2018/082191 WO2019195959A1 (en) 2018-04-08 2018-04-08 Combination therapy for cancers with braf mutation
CNPCT/CN2018/082191 2018-04-08
PCT/CN2019/081674 WO2019196764A1 (en) 2018-04-08 2019-04-08 Combination therapy for cancers with braf mutation

Publications (2)

Publication Number Publication Date
JP2021520406A true JP2021520406A (ja) 2021-08-19
JP2021520406A5 JP2021520406A5 (cg-RX-API-DMAC7.html) 2022-04-15

Family

ID=68163067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503193A Pending JP2021520406A (ja) 2018-04-08 2019-04-08 Braf変異を有するがんのための組合せ治療

Country Status (6)

Country Link
US (2) US11753476B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773719A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021520406A (cg-RX-API-DMAC7.html)
CN (2) CN121313846A (cg-RX-API-DMAC7.html)
AU (1) AU2019251124B2 (cg-RX-API-DMAC7.html)
WO (2) WO2019195959A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516828A (ja) * 2021-04-30 2024-04-17 シティ・オブ・ホープ がん治療のためのpcna阻害剤及びegfr阻害剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
WO2021068868A1 (en) * 2019-10-09 2021-04-15 Cothera Bioscience, Inc. Combination therapy for cancers with kras mutation
CA3186465A1 (en) * 2019-10-22 2021-04-29 Chemistry Rx Methods for treating congenital epidermal hyperplasia
BR112023014751A2 (pt) * 2021-01-25 2023-10-03 Ikena Oncology Inc Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN115944625A (zh) * 2022-09-05 2023-04-11 湖南灵康医疗科技有限公司 一种黑色素瘤治疗药物组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors
JP2013537544A (ja) * 2010-08-17 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌剤併用療法
JP2015523397A (ja) * 2012-07-26 2015-08-13 ノバルティス アーゲー Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬
JP2017502013A (ja) * 2013-12-20 2017-01-19 バイオメッド バレー ディスカバリーズ,インコーポレイティド Cdk阻害剤およびerk阻害剤の組み合わせを使用するがん処置

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965362A (en) 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
HU221001B1 (hu) 1994-03-17 2002-07-29 Merck Patent Gmbh. Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
PT1256576E (pt) 2000-02-15 2005-09-30 Astellas Pharma Inc Derivados de imidazolio fundidos
WO2002066058A1 (en) 2001-02-19 2002-08-29 Merck Patent Gmbh Modified anti-egfr antibodies with reduced immunogenicity
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR101015034B1 (ko) 2003-04-15 2011-02-16 아스텔라스세이야쿠 가부시키가이샤 브롬화물 및 이의 결정
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
BRPI0509580A (pt) 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
JPWO2005111213A1 (ja) 2004-05-18 2008-03-27 学校法人 久留米大学 Myc標的遺伝子mimitin
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
JP2009515878A (ja) 2005-11-12 2009-04-16 イーライ リリー アンド カンパニー 抗egfr抗体
JP4806776B2 (ja) 2006-01-27 2011-11-02 国立大学法人 千葉大学 c−myc遺伝子転写抑制因子FIRのスプライシングバリアント又はイントロン2内の4塩基繰り返し配列による癌検出方法
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
EP2055304A1 (en) 2006-08-25 2009-05-06 Astellas Pharma Inc. Stabilized pharmaceutical composition
US8227605B2 (en) 2006-10-31 2012-07-24 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
CA2703979A1 (en) 2007-10-29 2009-05-07 Schering Corporation Heterocyclic ether and thioether derivatives and methods of use thereof
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
WO2010056931A1 (en) 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
CA2789696C (en) * 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
JP2014156400A (ja) 2011-05-24 2014-08-28 Astellas Pharma Inc 腫瘍の画像診断用標識誘導体
WO2012167099A1 (en) 2011-06-01 2012-12-06 Baylor College Of Medicine Biomarkers and therapy for cancer
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
US20130122005A1 (en) * 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
RU2014122048A (ru) 2011-11-16 2015-12-27 Онкомед Фармасьютикалс, Инк. Мутации рецептора notch человека и их применение
WO2013148649A1 (en) 2012-03-26 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of survivin antagonists in polyomavirus-related disease
EP2945628B1 (en) 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US20160024591A1 (en) 2013-03-14 2016-01-28 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
US9913844B2 (en) 2013-03-21 2018-03-13 Novartis Ag Combination therapy
US9314460B1 (en) 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
KR101514877B1 (ko) 2013-05-06 2015-04-24 조선대학교산학협력단 APE/Ref -1 및 JAG1/Notch의 대장암 진단용 마커로서의 용도
US20170080093A1 (en) 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
BR112016014481B1 (pt) * 2013-12-20 2022-11-08 Biomed Valley Discoveries, Inc Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
US20200237758A1 (en) 2014-04-04 2020-07-30 Astrazeneca Ab Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
SG11201610534UA (en) * 2014-06-16 2017-01-27 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
BR112017025045A2 (pt) 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
WO2017019279A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
US20180243304A1 (en) 2015-08-28 2018-08-30 Novartis Ag Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
AU2016315878A1 (en) 2015-09-03 2018-03-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3349774A4 (en) 2015-09-15 2019-03-27 Swedish Health Services METHOD AND COMPOSITE SHEETS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS THEREOF
WO2017070475A1 (en) 2015-10-22 2017-04-27 Merrimack Pharmaceuticals, Inc. Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies
AU2017205478A1 (en) 2016-01-07 2018-06-28 Swadesh K. Das A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
WO2017143237A1 (en) 2016-02-17 2017-08-24 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
TW201813644A (zh) * 2016-09-23 2018-04-16 江蘇恆瑞醫藥股份有限公司 酪胺酸激酶抑制劑在製備治療癌症藥物中的用途
WO2018127786A1 (en) 2017-01-06 2018-07-12 Oslo Universitetssykehus Hf Compositions and methods for determining a treatment course of action
CN106822905B (zh) 2017-03-08 2019-05-17 暨南大学 含Survivin抑制剂和IRE1抑制剂的药物及用途
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
US12571049B2 (en) 2018-03-21 2026-03-10 Dana-Farber Cancer Institute, Inc. Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2020034061A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co., Ltd. Biomarkers for cancer therapy
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
WO2020097901A1 (en) 2018-11-16 2020-05-22 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537544A (ja) * 2010-08-17 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌剤併用療法
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors
JP2015523397A (ja) * 2012-07-26 2015-08-13 ノバルティス アーゲー Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬
JP2017502013A (ja) * 2013-12-20 2017-01-19 バイオメッド バレー ディスカバリーズ,インコーポレイティド Cdk阻害剤およびerk阻害剤の組み合わせを使用するがん処置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 20, no. 14, JPN6023015780, 2014, pages 3775 - 3786, ISSN: 0005197821 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516828A (ja) * 2021-04-30 2024-04-17 シティ・オブ・ホープ がん治療のためのpcna阻害剤及びegfr阻害剤

Also Published As

Publication number Publication date
WO2019196764A1 (en) 2019-10-17
EP3773719A4 (en) 2022-03-02
US20210179718A1 (en) 2021-06-17
EP3773719A1 (en) 2021-02-17
US11753476B2 (en) 2023-09-12
CN112566660B (zh) 2025-10-21
AU2019251124A1 (en) 2020-10-22
AU2019251124B2 (en) 2026-01-08
CN121313846A (zh) 2026-01-13
WO2019195959A1 (en) 2019-10-17
CN112566660A (zh) 2021-03-26
US20240059778A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
US20240059778A1 (en) Combination therapy for cancers with braf mutation
JP6742391B2 (ja) 併用療法
AU2013299841B8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
JP2023145689A (ja) Her2陽性がんの処置
TW202342047A (zh) 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
US20240058339A1 (en) Combination therapy for cancers with kras mutation
WO2021068867A1 (en) Combination therapy for cancers with kras mutation
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231115